All In Biotech

Drug Trial Radar · NCT02871492

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax®) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1

Last checked: Nov 19, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

362

Actual

Start

Nov 29, 2016

Primary completion

Sep 29, 2017

Study completion Oct 16, 2017

Sponsor

Sponsor type
Industry
Collaborators
Novella Clinical
First posted
Aug 18, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent herpes labialis (RHL) in comparison with placebo or Zovirax® Cream. The start of treatment with trial medication will be initiated by the subject within one hour of noticing the first sign or symptom (eg, prodrome) of a recurrence of herpes labialis. Trial medication will be applied to the affected area 5 times daily for 4 days. After self-initiation of treatment with trial medication subjects will be assessed daily by the Investigator until complete healing for a maximum of 13 days. Subjects will document application of trial medication and the status of their lesion in a diary. There will also be blood sampling, ECG measurement and physical examination performed at the investigational site.

Conditions

  • Herpes Labialis

Interventions

  • Pritelivir 5% w/w ointmentDrug

  • Pritelivir ointment matching placeboDrug

  • Zovirax® creamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's AssessmentTime frame: 13 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Santa Rosa, California

  • Site not named

    Pinellas Park, Florida

  • Site not named

    Edina, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Anderson, South Carolina

  • Site not named

    Greer, South Carolina

  • Site not named

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.